Medison And Alnylam Announce Expansion Of Multi-Regional Partnership In Europe And Israel To Commercialize RNAi Therapeutics In Additional LATAM And APAC markets
Portfolio Pulse from Benzinga Newsdesk
Medison and Alnylam Pharmaceuticals have expanded their partnership to commercialize RNAi therapeutics in additional markets in Latin America (LATAM) and the Asia-Pacific (APAC) region, building on their existing collaboration in Europe and Israel.
April 30, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals expands its commercialization partnership with Medison into LATAM and APAC, aiming to enhance its global footprint in the RNAi therapeutics market.
The expansion of Alnylam's partnership with Medison into new markets is likely to positively impact ALNY's stock in the short term due to the potential for increased market penetration and revenue growth in LATAM and APAC regions. This strategic move demonstrates Alnylam's commitment to expanding its global presence and could be viewed favorably by investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90